Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVX-V1
- Development stage
- Preclinical
- Lead developer
- Evaxion Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
01
Overview
EVX-V1 is a synthetic, multi-component vaccine candidate under preclinical development for the prevention of cytomegalovirus (CMV) infections. Developed by Evaxion Biotech in collaboration with ExpreS2ion Biotechnologies, it leverages antigens identified using Evaxion’s proprietary AI-Immunology™ platform. The vaccine includes a novel prefusion glycoprotein B (gB) antigen designed to induce both B and T cell responses and neutralize CMV. The approach aims to provide broader protection than traditional vaccines by targeting multiple viral antigens simultaneously. As of June 2025, no approved CMV vaccines exist; EVX-V1 is being developed primarily for immunocompromised individuals and populations at risk of congenital CMV infection[1][3][4][7].
- Brand names
- EVX-V1EVX-V-1EVX-V 1
- Other names
- Cytomegalovirus vaccine - Evaxion Biotech
02
Targets
γδ TCR (T-cell receptor)BCR (Immunoglobulin G B Cell Receptor)
Beyond the preview
Go deeper on EVX-V1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVX-V1.